Brachytherapy and proton therapy are radiation therapies, while HIFU and TULSA are focal therapies with distinct mechanisms. Medicare typically covers HIFU but not TULSA, with potential future ...
Men with prostate cancer stage cT1c-T2bN0M0, Gleason Score (GS) 2-6 and prostate-specific antigen (PSA) 10-20 or GS 7, and PSA < 10 were eligible. The COMBO arm was EBRT (45 Gy in 25 fractions) to ...
SIRFLOX: Randomized Phase III Trial Comparing First-Line mFOLFOX6 (Plus or Minus Bevacizumab) Versus mFOLFOX6 (Plus or Minus Bevacizumab) Plus Selective Internal Radiation Therapy in Patients With ...
A newly developed long-term prediction model demonstrated greater accuracy in estimating prostate cancer–specific mortality compared with existing risk assessment tools. Unlike traditional ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results